Jazz Pharmaceuticals JAZZ Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's cash & equivalents?
- Jazz Pharmaceuticals (JAZZ) reported cash & equivalents of $667.5M in Q1 2026.
- How has Jazz Pharmaceuticals's cash & equivalents changed year-over-year?
- Jazz Pharmaceuticals's cash & equivalents decreased by 64.1% year-over-year, from $1.86B to $667.5M.
- What is the long-term trend for Jazz Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's cash & equivalents has grown at a -8.4% compound annual growth rate (CAGR), from $1.06B to $682.7M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets the company has on hand.
- How do you interpret cash & equivalents?
- An increase suggests strong liquidity and potential for investment, while a decrease may indicate cash burn or significant capital deployment.
- How does cash & equivalents compare across companies?
- Standard across all industries; peers in biopharma typically maintain high levels to support R&D and M&A.